National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection (vol 41, pg 1125, 2005)

被引：0
|
作者：
McElroy, PD
Ijaz, K
Lambert, LA
Jereb, JA
Iademarco, MF
Castro, KG
Navin, TR
机构：
来源：
CLINICAL INFECTIOUS DISEASES | 2006年 / 42卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：313 / 313
页数：1
相关论文
共 9 条
  • [1] National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection
    McElroy, PD
    Ijaz, K
    Lambert, LA
    Jereb, JA
    Iademarco, MF
    Castro, KG
    Navin, TR
    CLINICAL INFECTIOUS DISEASES, 2005, 41 (08) : 1125 - 1133
  • [2] Fatal liver injury associated with rifampin-pyrazinamide treatment of latent tuberculosis infection
    Castro, KG
    Jereb, JA
    Koppaka, VR
    Cohn, DL
    CHEST, 2003, 123 (03) : 967 - 967
  • [3] Severe or fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide for latent tuberculosis infection
    Ijaz, K
    Jereb, JA
    Lambert, LA
    Bower, WA
    Spradling, PR
    McElroy, PD
    Iademarco, MF
    Navin, TR
    Castro, KG
    CLINICAL INFECTIOUS DISEASES, 2006, 42 (03) : 346 - 355
  • [4] Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection (Reprinted from MMWR, vol 51, pg 998-999, 2002)
    Lambert, L
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (23): : 2967 - 2967
  • [5] Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations - United States, 2001
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2001, 164 (07) : 1319 - 1320
  • [6] Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection - New York and Georgia, 2000 (Reprinted from MMWR, vol 50, pg 289-291, 2001)
    DeMartino, M
    Maniscalco, J
    Greenberg, A
    Grabau, J
    Oxtoby, M
    Foster, E
    Smith, P
    Kozarsky, P
    Pox, C
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (20): : 2572 - 2573
  • [7] Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected by the human immunodeficiency virus? (vol 9, pg 276, 2005)
    Tortajada, C
    Martínez-Lacasa, J
    Sánchez, F
    Jiménez-Fuentes, A
    De Souza, ML
    García, JF
    Martínez, JA
    Caylà, JA
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2005, 9 (06) : 706 - 706
  • [8] Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations - United States, 2001 (Reprinted from MMWR, vol 50, pg 733-735, 2001)
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (12): : 1445 - 1446
  • [9] Severe Isoniazid-Associated Liver Injuries Among Persons Being Treated for Latent Tuberculosis Infection-United States, 2004-2008 (Reprinted from JAMA, vol 59, pg 224-229, 2010)
    Harrington, T.
    Manangan, L.
    Jereb, J.
    Navin, T.
    Powell, K.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 303 (15): : 1471 - 1473
1